Assetmark Inc. Buys 775 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Assetmark Inc. lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 77,500.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 776 shares of the company’s stock after acquiring an additional 775 shares during the quarter. Assetmark Inc.’s holdings in Vaxcyte were worth $64,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Amalgamated Bank lifted its position in shares of Vaxcyte by 8.6% in the third quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock worth $466,000 after buying an additional 322 shares in the last quarter. Principal Financial Group Inc. raised its position in Vaxcyte by 186.2% in the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock worth $6,022,000 after purchasing an additional 34,287 shares during the period. Atria Investments Inc bought a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $286,000. Los Angeles Capital Management LLC purchased a new stake in shares of Vaxcyte during the third quarter valued at $1,016,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in Vaxcyte by 24.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 5,649 shares of the company’s stock worth $646,000 after acquiring an additional 1,120 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Performance

PCVX opened at $74.37 on Friday. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06. The business’s 50-day simple moving average is $82.24 and its 200-day simple moving average is $94.36. The company has a market cap of $9.58 billion, a P/E ratio of -16.17 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. As a group, analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now owns 205,695 shares in the company, valued at $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,250 shares of company stock valued at $4,550,258. 3.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PCVX shares. Needham & Company LLC restated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.